• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Product › Details

virostatic agent

	Next higher product group	anti-infective drug
	Status	1998-01-01 sales existent

Record changed: 2020-05-15

Advertisement

More documents for virostatic agent

• [1] AiCuris Anti-infective Cures GmbH. (6/9/20). "Press Release: Royalty Pharma Acquires Partial Royalty Interest on Prevymis (Letermovir) from AiCuris Anti-infective Cures GmbH". New York, NY & Wuppertal....
• [2] Innovative Medicines Initiative (IMI). (5/12/20). "Press Release: IMI Announces COVID Projects, Boosts Funding Pot to EUR 72 million". Brussels....
• [3] GlaxoSmithKline plc. (4/6/20). "Press Release: GSK and Vir Biotechnology Enter Collaboration to Find Coronavirus Solutions". London & San Francisco, CA....
• [4] Exscientia Ltd.. (3/31/20). "Press Release: Exscientia Announces Joint Initiative to Identify COVID-19 Drugs with Diamond Light Source and Scripps Research"....
• [5] Gilead Sciences, Inc.. (2/4/20). "Press Release: Gilead Sciences Announces Fourth Quarter and Full Year 2019 Financial Results". Foster City, CA....
• [6] GlaxoSmithKline plc. (1/8/20). "Press Release: Deborah Waterhouse, CEO of ViiV Healthcare, to Join GSK Corporate Executive Team (CET)". London....
• [7] ReViral Ltd.. (10/21/19). "Press Release: ReViral Announces Appointment of Alan Musso as Chief Financial Officer". London....
• [8] GlaxoSmithKline plc. (8/22/19). "Press Release: ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-treatment Regimen Administered every Two Months". London....
• [9] Gilead Sciences, Inc.. (7/19/19). "Press Release: Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis". Foster City, CA....
• [10] GlaxoSmithKline plc. (7/3/19). "Press Release: ViiV Healthcare Receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection". London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2020. Made in Germany.